Correlation Engine 2.0
Clear Search sequence regions
Bookmark Forward

QuickView for Oxaprozin (compound)

Name: oxaprozin
PubChem Compound ID: 4614
Molecular formula: C18H15NO3
Molecular weight: 293.317 g/mol
Xopane; NCI60_002681; 3-(4, 5-Diphenyl-2-oxazolyl)propenoic acid; Oxaprozina [INN-Spanish]; SPBio_001652; Duraprox; NSC 310839; KBioGR_001722; WY 21743; NCIStruc2_000787.
show more »
Name: oxaprozin
Name (isomeric): DB00991
Drug Type: small molecule
Oxaprozine [INN-French]; Oxaprozina [INN-Spanish]; Oxaprozinum [INN-Latin]
Brand: Deflam, Voir, Daypro, Daypro Alta, Alvo
Category: Anti-inflammatory Agents, Nonsteroidal Anti-inflammatory Agents (NSAIAs)
CAS number: 21256-18-8
Indication: Used to relieve the inflammation, swelling, stiffness, and joint pain associated with rheumatoid arthritis and osteoarthritis.
Pharmacology: Oxaprozin is a nonsteroidal anti-inflammatory drug (NSAID) with analgesic and antipyretic properties. Oxaprozin is used to treat rheumatoid arthritis, osteoarthritis, dysmenorrhea, and to alleviate moderate pain.
Mechanism of Action:
Anti-inflammatory effects of Oxaprozin are believed to be due to inhibition of cylooxygenase in platelets which leads to the blockage of prostaglandin synthesis. Antipyretic effects may be due to action on the hypothalamus, resulting in an increased peripheral blood flow, vasodilation, and subsequent heat dissipation. Oxaprozin is a non-selective N...
show more »
Absorption: Oxaprozin is 95% absorbed after oral administration. Food may reduce the rate of absorption of oxaprozin, but the extent of absorption is unchanged. Antacids do not significantly affect the extent and rate of oxaprozin absorption.
Protein binding: >99.5% bound to albumin
Biotransformation: Hepatic. Ester and ether glucuronide are the major conjugated metabolites of oxaprozin, and do not have significant pharmacologic activity.
Route of elimination: Oxaprozin is expected to be excreted in human milk based on its physical-chemical properties; however, the amount of oxaprozin excreted in breast milk has not been evaluated. Approximately 95% of oxaprozin is metabolized by the liver. Approximately 5% of the oxaprozin dose is excreted unchanged in the urine. Sixty-five percent (65%) of the dose is excreted in the urine and 35% in the feces as metabolite. Biliary excretion of unchanged oxaprozin is a minor pathway. Several oxaprozin metabolites have been identified in human urine or feces.
Half Life: 54.9 hours
Toxicity: Oral, mouse: LD50 = 1210 mg/kg; Oral, rabbit: LD50 = 172 mg/kg; Oral, rat: LD50 = 4470 mg/kg
Affected organisms: Humans and other mammals
Food interaction:
Take with food, usually once a day after breakfast. Food decreases the rate of absorption but not the amount absorbed. Avoid alcohol.
Drug interaction:
DicumarolThe NSAID, oxaprozin, may increase the anticoagulant effect of dicumarol.
TreprostinilThe prostacyclin analogue, Treprostinil, may increase the risk of bleeding when combined with the NSAID, Oxaprozin. Monitor for increased bleeding during concomitant thearpy.
WarfarinThe antiplatelet effects of oxaprozin may increase the bleed risk associated with warfarin. Consider alternate therapy or monitor for signs and symptoms of bleeding during concomitant therapy.
TelmisartanConcomitant use of Telmisartan and Oxaprozin may increase the risk of acute renal failure and hyperkalemia. Monitor renal function at the beginning and during treatment.
TimololThe NSAID, Oxaprozin, may antagonize the antihypertensive effect of Timolol.
show more »